Compare RJF & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJF | DXCM |
|---|---|---|
| Founded | 1962 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 34.4B |
| IPO Year | 2005 | 2005 |
| Metric | RJF | DXCM |
|---|---|---|
| Price | $166.29 | $81.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 29 |
| Target Price | ★ $182.21 | $98.58 |
| AVG Volume (30 Days) | 1.0M | ★ 4.6M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | 6.19 | ★ 47.18 |
| EPS | ★ 8.52 | 1.87 |
| Revenue | ★ $15,912,000,000.00 | N/A |
| Revenue This Year | $11.44 | $12.15 |
| Revenue Next Year | $7.03 | $10.45 |
| P/E Ratio | ★ $19.74 | $44.71 |
| Revenue Growth | ★ 6.63 | N/A |
| 52 Week Low | $138.82 | $56.72 |
| 52 Week High | $182.73 | $92.59 |
| Indicator | RJF | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 48.61 |
| Support Level | $163.01 | $62.02 |
| Resistance Level | $173.14 | $90.89 |
| Average True Range (ATR) | 4.20 | 2.96 |
| MACD | 0.81 | 0.19 |
| Stochastic Oscillator | 63.37 | 34.32 |
Raymond James Financial is a diversified financial services firm that provides wealth management, investment banking, asset management, and capital markets services to individuals, corporations, and municipalities. The firm maintains an extensive catalog of products and services across its business lines. However, the wealth management franchise generates the bulk of its revenue and earnings through a vast network of more than 8,900 independent and employee-affiliated advisors, who collectively managed over $1.9 trillion in client assets as of fiscal year-end 2026. While Raymond James maintains a global footprint, the company derives more than 90% of its revenue and an even larger percentage of its operating income from the United States.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.